Another hot field in the CML scenario is represented by the adoption of the NGS tools for evaluating the mutations of the ABL1 kinase domain, these being the mutations responsible for resistance to TKIs either in the chronic or in more advanced disease phases. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.